Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics

Aldosterone is synthesised by aldosterone synthase (CYP11B2). CYP11B2 has a highly homologous isoform, steroid 11β-hydroxylase (CYP11B1), which is responsible for the biosynthesis of aldosterone precursors and glucocorticoids. To investigate aldosterone biosynthesis and facilitate the search for selective CYP11B2 inhibitors, we constructed three-dimensional models for CYP11B1 and CYP11B2 for both human and rat. The models were constructed based on the crystal structure of Pseudomonas Putida CYP101 and Oryctolagus Cuniculus CYP2C5. Small steric active site differences between the isoforms were found to be the most important determinants for the regioselective steroid synthesis. A possible explanation for these steric differences for the selective synthesis of aldosterone by CYP11B2 is presented. The activities of the known CYP11B inhibitors metyrapone, R-etomidate, R-fadrazole and S-fadrazole were determined using assays of V79MZ cells that express human CYP11B1 and CYP11B2, respectively. By investigating the inhibitors in the human CYP11B models using molecular docking and molecular dynamics simulations we were able to predict a similar trend in potency for the inhibitors as found in the in vitro assays. Importantly, based on the docking and dynamics simulations it is possible to understand the enantioselectivity of the human enzymes for the inhibitor fadrazole, the R-enantiomer being selective for CYP11B2 and the S-enantiomer being selective for CYP11B1.

[1]  J. Connell,et al.  Effects of 18-hydroxylated steroids on corticosteroid production by human aldosterone synthase and 11beta-hydroxylase. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[3]  Andrew Howard,et al.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam , 1993 .

[4]  D. Lewis,et al.  Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. , 1998, Mutation research.

[5]  B. Erdmann,et al.  Human adrenal CYP11B1: localization by in situ-hybridization and functional expression in cell cultures. , 1995, Endocrine research.

[6]  D S Moss,et al.  Main-chain bond lengths and bond angles in protein structures. , 1993, Journal of molecular biology.

[7]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[8]  U. Heinemann,et al.  Adrenodoxin: Structure, stability, and electron transfer properties , 2000, Proteins.

[9]  S. Imaoka,et al.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.

[10]  Nico P. E. Vermeulen,et al.  A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..

[11]  Ferran Sanz,et al.  Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ , 1997, J. Comput. Aided Mol. Des..

[12]  J. Halpert,et al.  Distinct binding of cholesterol and 5β-cholestane-3α,7α,12α-triol to cytochrome P450 27A1 : Evidence from modeling and site-directed mutagenesis studies , 2006 .

[13]  R. Brueggemeier,et al.  The final catalytic step of cytochrome p450 aromatase: a density functional theory study. , 2005, Journal of the American Chemical Society.

[14]  H. Dörr,et al.  Etomidate: A selective adrenocortical 11β-hydroxylase inhibitor , 1984, Klinische Wochenschrift.

[15]  Joël Ménard,et al.  The 45-year story of the development of an anti-aldosterone more specific than spironolactone , 2004, Molecular and Cellular Endocrinology.

[16]  A. Cavalli,et al.  Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors. , 2000, Bioorganic & medicinal chemistry.

[17]  K. Yanagibashi,et al.  The synthesis of aldosterone by the adrenal cortex. Two zones (fasciculata and glomerulosa) possess one enzyme for 11 beta-, 18-hydroxylation, and aldehyde synthesis. , 1986, The Journal of biological chemistry.

[18]  R. Bernhardt,et al.  Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. , 2001, Journal of inorganic biochemistry.

[19]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[20]  Andrea Brancale,et al.  Homology model of 1α,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): Active site architecture and ligand binding , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  J. Salerno,et al.  Molecular modeling of the 3-D structure of cytochrome P-450scc. , 1992, Biochimica et biophysica acta.

[22]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[23]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[24]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[25]  R. Bernhardt,et al.  Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. , 1998, European journal of biochemistry.

[26]  J. Peterson,et al.  How similar are P450s and what can their differences teach us? , 1999, Archives of biochemistry and biophysics.

[27]  G H Loew,et al.  Construction of a 3D model of cytochrome P450 2B4. , 1997, Protein engineering.

[28]  M. Okamoto,et al.  Functional expression of the cDNAs encoding rat 11β-hydroxylase [cytochrome P450(11β)] and aldosterone synthase [cytochrome P450(11β, aldo)] , 1991 .

[29]  M. Okamoto,et al.  Frog cytochrome P-450 (11 beta,aldo), a single enzyme involved in the final steps of glucocorticoid and mineralocorticoid biosynthesis. , 1995, European journal of biochemistry.

[30]  N. Ibrahim,et al.  Aromatase inhibitors in breast cancer: an overview. , 2006, The oncologist.

[31]  R. Hartmann,et al.  Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. , 2003, European journal of medicinal chemistry.

[32]  A. Warshel,et al.  Examining methods for calculations of binding free energies: LRA, LIE, PDLD‐LRA, and PDLD/S‐LRA calculations of ligands binding to an HIV protease , 2000, Proteins.

[33]  L. Nieman,et al.  The Metyrapone and Dexamethasone Suppression Tests for the Differential Diagnosis of the Adrenocorticotropin-Dependent Cushing Syndrome: A Comparison , 1994, Annals of Internal Medicine.

[34]  M. Okamoto,et al.  Synthesis of aldosterone by a reconstituted system of cytochrome P-45011 beta from bovine adrenocortical mitochondria. , 1985, Journal of biochemistry.

[35]  G. N. Ramachandran,et al.  Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.

[36]  M. Saraste,et al.  FEBS Lett , 2000 .

[37]  Jürgen Pleiss,et al.  Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: The molecular basis of substrate binding and regioselectivity toward warfarin , 2006, Proteins.

[38]  H. Schrauber,et al.  Engineering a Mineralocorticoid- to a Glucocorticoid-synthesizing Cytochrome P450 (*) , 1996, The Journal of Biological Chemistry.

[39]  김삼묘,et al.  “Bioinformatics” 특집을 내면서 , 2000 .

[40]  A. Matter,et al.  CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. , 1988, Cancer research.

[41]  D. Koop,et al.  Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. , 1994, The Journal of pharmacology and experimental therapeutics.

[42]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[43]  D. Duprez,et al.  Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.

[44]  A. J. Byrne,et al.  Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. , 1983, British medical journal.

[45]  J. Connell,et al.  The new biology of aldosterone. , 2005, The Journal of endocrinology.

[46]  J. Doehmer,et al.  Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. , 1995, Endocrine research.

[47]  J. Peterson,et al.  Cholesterol binding to cytochrome P450 7A1, a key enzyme in bile acid biosynthesis. , 2005, Biochemistry.

[48]  J. Peterson,et al.  A close family resemblance: the importance of structure in understanding cytochromes P450. , 1998, Structure.

[49]  R. Estabrook,et al.  Probing the interaction of bovine cytochrome P450scc (CYP11A1) with adrenodoxin: evaluating site-directed mutations by molecular modeling. , 2002, Biochemistry.

[50]  Thomas Lengauer,et al.  Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. , 2005, Journal of medicinal chemistry.

[51]  J. López-Sendón,et al.  The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.

[52]  H. Krum,et al.  Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients , 2002, Hypertension.

[53]  D. Sica Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.

[54]  M. Seldin,et al.  Different isozymes of mouse 11 beta-hydroxylase produce mineralocorticoids and glucocorticoids. , 1991, Molecular endocrinology.

[55]  P. Furet,et al.  Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. , 1993, Journal of medicinal chemistry.

[56]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[57]  M. Murray,et al.  Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. , 1987, Drug metabolism reviews.

[58]  Hans-Dieter Höltje,et al.  Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole , 2005, J. Comput. Aided Mol. Des..

[59]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[60]  A. Cavalli,et al.  Nonsteroidal aromatase inhibitors: Recent advances , 2002, Medicinal research reviews.

[61]  R. Raag,et al.  Cytochrome P450cam: crystallography, oxygen activation, and electron transfer1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  C. Delcayre,et al.  Cardiac aldosterone production and ventricular remodeling. , 2000, Kidney international.

[63]  R. Santen,et al.  The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. , 1990, The Journal of clinical endocrinology and metabolism.

[64]  J. Liu,et al.  Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.

[65]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[66]  A. Struthers Aldosterone: cardiovascular assault. , 2002, American heart journal.

[67]  J. O. Johnston,et al.  Enzyme-activated inhibitors of steroidal hydroxylases , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[68]  J Deisenhofer,et al.  Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.

[69]  Toshimasa Tanaka,et al.  Characterization of the CYP3A4 active site by homology modeling. , 2004, Chemical & pharmaceutical bulletin.

[70]  O. Weinberg,et al.  New approaches to reverse resistance to hormonal therapy in human breast cancer. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[71]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[72]  Geoffrey J. Barton,et al.  JPred : a consensus secondary structure prediction server , 1999 .

[73]  D. Case,et al.  Optimized particle-mesh Ewald/multiple-time step integration for molecular dynamics simulations , 2001 .

[74]  K. Nakao,et al.  Cloning of cDNA and genomic DNA for human cytochrome P‐45011β , 1990, FEBS letters.

[75]  國郎 小笠原,et al.  Chem. Pharm. Bull.(オピニオン) , 2007 .